Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

Pharma major Dr. Reddy’s Laboratories Ltd. on Thursday announced its consolidated financial results for the quarter and nine ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

A bill introduced this legislative session aims to prohibit the sale of certain marijuana products to customers aged 21 to 25 ...

FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

The India business saw a revenue growth of 14% year-on-year in ... pick-up in certain brands in cardiac and gastro-intestinal therapy areas, the company said. While the pharma major's India ...